Ocata Therapeutics Company
%20.jpg)
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
Founded Date:
1-1
Total Funding:
$82.5M
Investor Type:
For Profit
Employee Number:
11-50
Funding Status:
M&A
Technology:
Regenerative Medicine
Last Funding Type:
Venture - Series Unknown
Investors Number:
13
Industry:
Biotechnology, Health Care, Therapeutics
Headquarters:
Marlborough, Massachusetts, United States
Estimated Revenue:
$10M to $50M